| Literature DB >> 29770107 |
Abhinav Parashar1, Daniel Andrew Gideon2, Kelath Murali Manoj3.
Abstract
Recently, electron transfers and catalyses in a bevy of redox reactions mediated by hemeproteins were explained by murburn concept. The term "murburn" is abstracted from "muredburning" or "mildunrestrictedburning" and connotes a novel "molecule-unbound ion-radical" interaction paradigm. Quite unlike the genetic regulations and protein-level affinity-based controls that govern order and specificity/selectivity in conventional treatments, murburn concept is based on stochastic/thermodynamic regulatory principles. The novel insight necessitates a "reactivity outside the active-site" perspective, because select redox enzymatic activity is obligatorily mediated via diffusible radical/species. Herein, reactions employing key hemeproteins (as exemplified by CYP2E1) establish direct experimental connection between "additive-influenced redox catalysis" and "unusual dose responses" in reductionist and physiological milieu. Thus, direct and conclusive molecular-level experimental evidence is presented, supporting the mechanistic relevance of murburn concept in "maverick" concentration-based effects brought about by additives. Therefore, murburn concept could potentially explain several physiological hormetic and idiosyncratic dose responses.Entities:
Keywords: cytochrome P450; drug metabolism; hemeprotein; hormetic dose response; idiosyncratic dose response; murburn concept
Year: 2018 PMID: 29770107 PMCID: PMC5946624 DOI: 10.1177/1559325818774421
Source DB: PubMed Journal: Dose Response ISSN: 1559-3258 Impact factor: 2.658
Figure 1.Profiling of CYP2E1 inhibitions over wide substrate and additives’ concentration ranges. The initial concentrations of reactants were 25 nmol/L CYP, 100 nmol/L CPR, 50 nmol/L Cyt b 5, 0.5 mmol/L NADP+ in regenerating system, and 0.02 mmol/L DLPC. Assay details have been described in our earlier works. CYP indicates cytochrome P450; CPR, cytochrome P450 reductase; Cyt b 5, cytochrome b 5; NADP, nicotinamide adenine dinucleotide; DLPC, dilauroyl phosphatidyl choline.
Figure 2.Variation of specific hydroxylated product formation rate as a function of additive concentration and sampling time. Inhibitor concentrations varied from 0 nmol/L, 10 nmol/L, 1 µmol/L, and 100 µmol/L. Substrate (pNP) = 100 µmol/L, 2E1 = 10 nmol/L, NADPH = 200 µmol/L, 2E1-pNP KM = 14 µmol/L. The velocity of reaction measured at 2 different time points was statistically analyzed by ANOVA. The mean rate (SD; n = 3) is represented as bars. Asterisks correspond to the respective significance herein: **** P < .0001; *** P < .001; ** P < .01; * P < .05; else P > .05. pNP indicates para-nitrophenol; NADPH, nicotinamide adenine dinucleotide phosphate; ANOVA, analysis of variance; SD, standard deviation.
Figure 3.Dose–response curves for baculosome preparations of CYP2E1-pNP system. Experimental conditions are as detailed in legends to Figure 2. Rate data within 10 minutes was used for relative activity calculation, with respect to the reaction mixture that lacked any additive. Since activations were also observed, the plots were fitted weighing 1 fmol/L as 99.99% and 1 M as 0.01%. (The error bars are not seen because of low standard deviations.). CYP indicates cytochrome P450; pNP, para-nitrophenol.
Classical Kinetic Constants Calculated for CYP2E1 Inhibitions.a,b
| Serial Number | Molecule | IC50 |
| Ki Competitive | Ki Uncompetitive | Ki Noncompetitive | Ki (Linear) |
|
|---|---|---|---|---|---|---|---|---|
| 1 | Bzbr | 126 (26) | −2.11 | 15.5 (3.1) | 110.5 | 126 | 785055 (478883) | 0.39 |
| 2 | Bzr | 71 (12) | 0.31 | 8.7 (1.4) | 62.3 | 71 | 195749 (64597) | 0.67 |
| 3 | Bzir | 3 (0.8) | −0.71 | 0.4 (0.1) | 2.6 | 3 | 126736 (31684) | 0.75 |
| 4 | MeOBzbr | 2 (0.4) | −0.24 | 0.2 (0.04) | 1.8 | 2 | 60534 (605) | 0.99 |
| 5 | MeOBzr | 115 (20) | 0.18 | 14.1 (2.5) | 100.9 | 115 | 1232197 (443591) | 0.64 |
| 6 | MeOBzir | 74 (15) | −0.27 | 9.1 (1.9) | 64.9 | 74 | 321218 (173458) | 0.46 |
| 7 | DIT | – | – | – | – | – | – | – |
| 8 | DBP | 29 (4) | 0.81 | 3.5 (0.5) | 25.4 | 29 | 14588 (584) | 0.96 |
| 9 | DBMP | 14 (1.7) | 0.91 | 1.8 (0.2) | 12.3 | 14 | 13521 (5408) | 0.60 |
| 10 | DBHBA | 1 (0.2) | 0.19 | 0.1 (0.02) | 0.9 | 1 | 34041 (1702) | 0.95 |
Abbreviations: CYP, cytochrome P450; Bzbr, benzbromarone; Bzr, benzarone; Bzir, benziodarone; IC50, half maximal inhibitory concentration; MeOBzbr, methoxybenzbromarone; MeOBzr, methoxybenzarone; MeOBzir, methoxybenziodarone; DIT, diiodotyrosine; DBP, dibromophenol; DBMP, dibromomethylphenol; DLPC, dilauroyl phosphatidyl choline; DBHBA, dibromohydroxybenzoic acid.
a All values are reported in µmol/L.
b Assay conditions are described in legends to the pertinent Figure 2. The IC50 values were derived with rates from early reaction time (10 minutes) data and only the experimental values were used for plotting/calculation. IC50 was calculated by nonlinear regression analysis from a log plot of inhibitor concentration versus percentage activity. The IC50 values thus obtained were used to determine Ki (for competitive inhibition) using Cheng-Prusoff equation (where [S] is the substrate concentration and KM is the Michaelis-Menten constant, taken to be 14 µmol/L): Ki = IC50/(1 + [S]/KM). Ki uncompetitive and Ki noncompetitive were calculated from the website (http://botdb.abcc.ncifcrf.gov/toxin/kiCalES.jsp). A linear regression method with a double logarithmic plot is also available for the calculation of Ki, as originally developed by Britton Chance. This equation, which does not use a KM value, is: log [Ri/(Ru − Ri)] = log Ki − log [I], where Ri and Ru are inhibited and uninhibited rates, respectively, obtained with the inhibitor concentration [I].
Docking of Ligands to CYP2E1.a
| Number | Flexible Ligand | Best Binding Parameters | |||
|---|---|---|---|---|---|
| ΔG (kcal/mol) | Distance (Å) | Amino Acids | Orientation | ||
| 1 | Para-nitrophenol (pNP) | −5.6 | 5.7 | VAL 364, LEU 368 | + |
| 2 | Chlorzoxazone | −6.0 | 21.4 | GLN 216, ASN 219 | − |
| 3 | Diclofenac | −6.9 | 17.2 | SER 472 | + |
| 4 | Quinoline | −6.6 | 4.9 | THR 303 | + |
| 5 | Isoquinoline (Isoquin) | −6.4 | 6.6 | ALA 299 | − |
| 6 | 3-Methylisoquinoline | −5.4 | 6.8 | ILE 115 | − |
| 7 | 4-Methylpyrazole (4-MetPyr) | −4.3 | 6.9 | ILE 115, THR 303 | − |
| 8 | 3-Methylxanthine (MetXan) | −5.8 | 8.8 | LEU 133, ALA 438, GLY 441 | − |
| 9 | Benzothiadiazole | −5.9 | 4.6 | THR 303 | − |
| 10 | Diiodotyrosine (DIT) | −6.2 | 19.2 | SER 74, GLN 75, ASP 102, ASN 220 | + |
| 11 | Dibromophenol (DBP) | −5.1 | 5.8 | ILE 115, LEU 368 | + |
| 12 | Dibromomethylphenol (DBMP) | −4.5 | 11.8 | LEU 133, ASN 143 | − |
| 13 | Dibromohydroxybenzoic acid (DBHBA) | −5.7 | 28.8 | ASP 470, LYS 486 | − |
| 15 | Benzarone (Bzr) | 4.8 | 10.4 | ASP 295 | − |
| 16 | Benzbromarone (Bzbr) | 2.6 | 10.4 | ASN 143, ILE 183, LEU 442 | − |
| 17 | Methoxybenzbromarone (MeOBzbr) | 4.0 | 9.6 | LEU 130, ASN 143 | − |
| 18 | Imidazole | −3.1 | 15.1 | THR 169, MET 200, SER 305 | + |
| 19 | 1-Methylimidazole | −3.5 | 5.4 | ALA 299 | + |
| 20 | 1-Aminopropylimidazole | −4.9 | 6.2 | PHE 298 | − |
| 21 | 4-Bromoimidazole | −4.0 | 4.0 | THR 303 | + |
| 22 | 4-Hyroxymethylimidazole | −4.2 | 6.2 | PHE 298, ALA 299, THR 303 | − |
| 23 | 4-Imidazole carboxylic acid | −4.7 | 4.2 | PHE 298, THR 303 | − |
| 24 | Pyridine | −4.5 | 5.4 | THR 303 | + |
| 25 | Pyrazine | −3.5 | 5.4 | ILE 115, ALA 299 | + |
| 26 | Piperazine | −3.6 | 26.3 | PHE 153, ASP 190 | − |
| 27 | Tiron | −6.5 | 13.7 | GLN 216, ASN 219, ASN 220 | − |
| 28 | Ascorbic acid | −5.4 | 12.6 | GLN 216, ASN 219, ASN 367 | + |
| 29 | 3-Aminobenzotriazole (ABT) | −6.2 | 6.1 | THR 303 | − |
a + indicates that the pertinent reactive/binding moiety is oriented toward the heme Fe, whereas − indicates that the same is oriented away from it.
Figure 4.Demonstration of nonspecific partnering with diverse combinations of hemeproteins, reductases, auxiliary redox partners, substrates, and electron donors. Head labels of each subfigure represent the constituents of control reactions. All the reactions were carried out at 27°C ± 1°C in 100 mmol/L potassium phosphate buffer (pH 7.4). The initial concentration of substrate employed was 200 µmol/L. Initial concentrations were as follows: [CPO] = 0.3 µmol/L, [CYP2E1] = 0.6 µmol/L, [NADH] = 360 µmol/L, and [H2O2] = 7.14 mmol/L. The levels of pNC at different time points were statistically analyzed by ANOVA. The mean pNC (SD; n = 3) is represented as bars. Significant differences for all CYP2E1 reactions were P < .01 (**) and for all CPO reactions were P < .05 (*). pNC indicates para-nitrocatechol; ANOVA, analysis of variance; SD, standard deviation; CPO, chloroperoxidase.
Simulation of Hydroxylating Activities of CYP2E1 With DROS.a
| Reaction | pNP | Cyt | ||
|---|---|---|---|---|
| CYP2E1 | Control | CYP2E1 | Control | |
| CPR+NADPH | 450 (51) | Trace | 786 (36) | Trace |
| H2O2 | <10 | Nil | ∼74 | Nil |
| O2 ˙− | ∼104b | ∼88b | ∼499b | ∼70b |
Abbreviations: CYP, cytochrome P450; DROS, diffusible reactive oxygen species; pNP, para-nitrophenol; Cyt b 5, cytochrome b 5; CPR, cytochrome P450 reductase; NADPH, nicotinamide adenine dinucleotide phosphate.
a Concentrations of hydroxylated products, formed after 10 minutes are in nmol/L. The experimental details are provided in “Methods” section.
b These reactions also showed nonspecific hydroxylations or side reactions.
Figure 5.Effect of azide (Azd) concentration on growth of a Gram-negative and Gram-positive bacteria. The data are represented as % OD (or relative growth) wrt the control sample at the corresponding time. The values in boxes above the control stand for the OD at 600 nm for the respective time periods. Averages for % control growth were within 10% of the absolute control values (test values normalized to control values in the figures). In (A), control value was 100 (9), 100 (7), and 100 (5) for 3 hours, 4 hours, and 4.5 hours, respectively. In (B), control value was 100 (9), 100 (5), and 100 (5) for 3 hours, 4 hours, and 5 hours, respectively.
Effect of Redox-Active Small Molecules and Enzymes on Growth of Escherichia coli DH5α.a
| Concentration (M) | Azide-CYP3A4 | Amitrol-Cyt | ||
|---|---|---|---|---|
| − IPTG | + IPTG | − IPTG | + IPTG | |
| Control | 100 | 95 (6) | 100 | 102 (5) |
| 10−3 | 12 (5) | 24 (3) | 94 (4) | 60 (9) |
| 10−6 | 97 (7) | 79 (5) | 103 (10) | 70 (6) |
| 10−9 | 41 (6) | 29 (6) | 103 (3) | 63 (5) |
| 10−12 | 107 (8) | 32 (3) | 50 (2) | 51 (4) |
Abbreviations: CYP, cytochrome P450; Cyt c, cytochrome c.
a Data shown are relative growth densities with respect to control (lacking both the additive and IPTG). For the controls of azide–CYP3A4 and amitrol–Cyt c cultures, the absolute OD values were 6 hours = 0.264 and 4 hours = 0.556. Other aspects are detailed in experimental descriptions.